In this edition of The OncoZine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company specialized in the development of Antibody-drug Conjugates. This Interview was recorded during the annual pharmaceutical industry meeting, CPhI Worldwide, held October 9 – 11, 2018 in Madrid, Spain. This edition was a co-production with ADC Review | the Journal of Antibody-drug Conjugates
In October, following the the pharmaceutical industry meeting CPhI World Wide, held October 4 – 6, 2016 in Barcelona, Spain, and the 10th International Symposium on Hodgkin Lymphoma (ISHL) in Cologne, Germany, held October 22- 25, 2016, we sat down with Anna Sureda MD Ph.D, Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme; Institut Català d’Oncologia – Hospital Duran i Reynals, to discuss some of the exciting developments involving the treatment of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma.
In an ongoing Phase II clinical study, sacituzumab govitecan has produced encouraging objective response rates and durable responses in heavily-pretreated patients with metastatic triple- negative breast (TNBC), small-cell and non-small-cell lung, and urothelial cancers.
Based on the preliminary announcements, this year, the annual meeting of the American Society of Hematology will indeed offer exciting data of ADC in the clinic as well as early and pre-clinical data showing great promise for the ongoing, successful, development of novel, innovative agents.